[go: up one dir, main page]

NO20062975L - Anvendelse av T-kadherin som et mal - Google Patents

Anvendelse av T-kadherin som et mal

Info

Publication number
NO20062975L
NO20062975L NO20062975A NO20062975A NO20062975L NO 20062975 L NO20062975 L NO 20062975L NO 20062975 A NO20062975 A NO 20062975A NO 20062975 A NO20062975 A NO 20062975A NO 20062975 L NO20062975 L NO 20062975L
Authority
NO
Norway
Prior art keywords
disorder
modulators
cadherin
metabolic
template
Prior art date
Application number
NO20062975A
Other languages
English (en)
Inventor
Christopher Hug
Harvey Lodish
Original Assignee
Whitehead Biomedical Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Whitehead Biomedical Inst filed Critical Whitehead Biomedical Inst
Publication of NO20062975L publication Critical patent/NO20062975L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Food Science & Technology (AREA)
  • Obesity (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)

Abstract

Den foreliggende oppfinnelsen angår bruken av T-kadherinpolypeptider for screening etter modulatorer av slike polypeptider, og anvendelsen av nevnte modulatorer for behandling av lidelser eUer sykdommer valgt fra gruppen bestående av en stoffskiftelidelse, en gynekologisk lidelse, en kronisk infiammatorisk lidelse og en lever- eUer nyrehdelse. Stoffskiftehdelser som kan behandles ved å bruke en modulator ifølge den foreliggende oppfirmelsen inkluderer for eksempel overvekt, type 11 diabetes, insulinresistens, hyperkolesterolemi, hyperlipidemi, dyslipidemi, syndrom X, kakeksi og anoreksi.
NO20062975A 2003-12-03 2006-06-26 Anvendelse av T-kadherin som et mal NO20062975L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52695603P 2003-12-03 2003-12-03
PCT/US2004/040363 WO2005057222A2 (en) 2003-12-03 2004-12-02 Use of t-cadherin as a target

Publications (1)

Publication Number Publication Date
NO20062975L true NO20062975L (no) 2006-06-26

Family

ID=34676687

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20062975A NO20062975L (no) 2003-12-03 2006-06-26 Anvendelse av T-kadherin som et mal

Country Status (18)

Country Link
US (1) US20070212686A1 (no)
EP (1) EP1701978B1 (no)
JP (1) JP2007519894A (no)
AT (1) ATE422506T1 (no)
AU (1) AU2004297914A1 (no)
CA (1) CA2546126A1 (no)
CY (1) CY1109014T1 (no)
DE (1) DE602004019451D1 (no)
DK (1) DK1701978T3 (no)
ES (1) ES2320139T3 (no)
HR (1) HRP20090119T3 (no)
IL (1) IL175862A (no)
NO (1) NO20062975L (no)
PL (1) PL1701978T3 (no)
PT (1) PT1701978E (no)
RS (1) RS50754B (no)
SI (1) SI1701978T1 (no)
WO (1) WO2005057222A2 (no)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2849559A1 (en) 2006-01-10 2007-07-19 Colgate-Palmolive Company Methods of modulating cell surface receptors to prevent or reduce inflammation
TWI405565B (zh) 2009-04-01 2013-08-21 Colgate Palmolive Co 口腔用組成物之抗－骨質流失及抗－牙周附連喪失之功效
CN102378629B (zh) 2009-04-01 2016-08-17 高露洁-棕榄公司 用于口部护理组合物的抗生物膜碳酸酯化合物
TWI481870B (zh) 2009-04-01 2015-04-21 Colgate Palmolive Co 用於軟組織疾病診斷及作為用於口腔保健干預的標靶之蛋白質生物標記
RU2492857C2 (ru) 2009-04-01 2013-09-20 Колгейт-Палмолив Компани Соединения - производные ментола и их применение в качестве активных системных агентов и агентов для ротовой полости
GB201312010D0 (en) * 2013-07-04 2013-08-21 Univ Birmingham Receptor Agonists
US11097005B2 (en) 2014-12-15 2021-08-24 The Brigham And Women's Hospital, Inc. Use of cadherin-11 antagonists to treat metabolic disorders and/or increase insulin sensitivity
EP4116711A4 (en) * 2020-03-03 2024-04-10 Tatsuya Sawamura ADIPONECTIN QUANTIFICATION METHOD AND ANALYTICAL REAGENT FOR USE IN SAID METHOD

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1023445B1 (de) * 1997-10-15 2005-08-17 Pharis Biotec GmbH Cadherin derived growth factor und seine verwendung
WO1999057149A2 (en) * 1998-05-05 1999-11-11 Adherex Technologies, Inc. Compounds and methods for modulating nonclassical cadherin-mediated functions
US6472367B1 (en) * 1998-05-05 2002-10-29 Adherex Technologies, Inc. Compounds and methods for modulating OB-cadherin mediated cell adhesion
US6680175B2 (en) * 1998-05-05 2004-01-20 Adherex Technologies, Inc. Methods for diagnosing and evaluating cancer
JP2003523192A (ja) * 2000-02-18 2003-08-05 ビオヴィトルム・アクチボラゲット Ｆｏｘｃ２を発現する肥満のトランスジェニック動物モデル
AU2001292658A1 (en) * 2000-09-13 2002-03-26 Eleanor Roosevelt Institute Method for treatment of insulin resistance in obesity and diabetes
AU2002240892A1 (en) * 2001-01-02 2002-07-16 Centre National De La Recherche Scientifique Protein-protein interactions in adipocyte cells
WO2004096272A2 (en) * 2003-04-29 2004-11-11 Cytos Biotechnology Ag Methods and compositions for modulating the interaction between adiponectin and its receptor
WO2005049861A2 (en) * 2003-11-10 2005-06-02 Epigenomics Ag Method for the analysis of gynaecological cell proliferative disorders

Also Published As

Publication number Publication date
JP2007519894A (ja) 2007-07-19
HRP20090119T3 (en) 2009-04-30
RS50754B (sr) 2010-08-31
AU2004297914A1 (en) 2005-06-23
WO2005057222A3 (en) 2006-02-23
EP1701978A2 (en) 2006-09-20
ES2320139T3 (es) 2009-05-19
CA2546126A1 (en) 2005-06-23
US20070212686A1 (en) 2007-09-13
WO2005057222A2 (en) 2005-06-23
PL1701978T3 (pl) 2009-07-31
CY1109014T1 (el) 2014-07-02
ATE422506T1 (de) 2009-02-15
PT1701978E (pt) 2009-03-03
SI1701978T1 (sl) 2009-08-31
EP1701978B1 (en) 2009-02-11
IL175862A0 (en) 2006-10-05
DK1701978T3 (da) 2009-04-06
IL175862A (en) 2010-11-30
DE602004019451D1 (de) 2009-03-26

Similar Documents

Publication Publication Date Title
NO20062975L (no) Anvendelse av T-kadherin som et mal
NO20035526D0 (no) Forbindelser for behandling av metabolske forstyrrelser
DK2060570T3 (da) Som modulatorer af dopamin-d3-receptorer anvendelige azabicyclo(3.1.0)hexanderivater
NO20074498L (no) PYY-agonister og anvendelser derav
DE60310731D1 (de) Neue, von noraporphin abgeleitete moleküle
BRPI0509207A (pt) moduladores canabinóides de tetraidro-indazol
UA96308C2 (ru) Антагонисты рецептора глюкагона, композиция, которая содержит такие соединения, и их применение
DK1761522T3 (da) Forbindelser og fremgangsmåder til behandling af dyslipidæmi
DE602006004964D1 (de) Dihydrochinazolinone als 5ht-modulatoren
DK1778236T3 (da) Modificerede pyrimidin-glucocorticoid-receptor-modulatorer
DE502006009413D1 (de) Quervernetzte polymere, diese enthaltende galvanisierungsbäder sowie deren verwendung
DK2350093T3 (da) Substituerede 4,5,6,7-tetrahydrothienopyridiner som KCNQ2/3-modulatorer til behandling af smerte, epilepsi og urininkontinens.
ATE462697T1 (de) Bisaryl-sulfonamide
FR2916659B1 (fr) Dispositif pour l'application ou la projection d'un materiau de densite elevee.
DE602007011495D1 (de) 1,5-DIPHENYL-3-BENZYLAMINO-1,5-DIHYDROPYRROLIDIN-2-ONE AlS CB1-REZEPTOR-MODULATOREN
NO20073369L (no) Modulatorer av muskarinreseptorer
TW200639428A (en) Light modulator device
ATE416221T1 (de) Schnell härtende polydiorganosiloxane
DE602005027400D1 (de) Il-22 zur behandlung von fettleibigkeit, diabetes, hyperlipidämie, hyperglykämie und insulinresistenz
DK1937259T3 (da) Hexahydro-cycloheptapyrazol-cannabinoid-modulatorer
ATE490269T1 (de) Kristallstruktur der trypanosoma cruzi proline racemase (tcpraca) und verwendung davon
ATE417816T1 (de) Anilinohexafluoroisopropanol verbindungen
EP1771435A4 (en) MODULATORS OF NEUROTRANSMITTERS OF THE CENTRAL NERVOUS SYSTEM
ATE416768T1 (de) Querverweise von tetrahydrothiopyrano-pyrazol- cannabinoidmodulatoren zu verwandten anmeldungen
NO20065800L (no) IL-13 bindingsmidler

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application